Literature DB >> 8030963

Generation and properties of measles virus mutations typically associated with subacute sclerosing panencephalitis.

M A Billeter1, R Cattaneo, P Spielhofer, K Kaelin, M Huber, A Schmid, K Baczko, V ter Meulen.   

Abstract

Subacute sclerosing panencephalitis (SSPE), a very rare but lethal disease caused by measles viruses (MV) persisting in the human central nervous system (CNS) is characterized by lack of viral budding, reduced expression of the viral envelope proteins and spread of MV genomes through the CNS despite massive immune responses. The five major MV genes from several SSPE cases were cloned and sequenced, the two transmembrane envelope glycoproteins hemagglutinin (H) and fusion protein (F) were expressed and their maturation, cellular localization and functionality analyzed. We conclude that 1) mutations in the MV genes arise not only individually, by errors of the MV polymerase, but also in clusters as hypermutations, presumably due to RNA unwinding/modifying activity altering accidentally formed double-stranded RNA regions, 2) MVs spread in SSPE brains after clonal selection, 3) the MV matrix (M) gene is most heavily mutated and dispensable, 4) the two genes encoding envelope transmembrane proteins give rise to functional but altered proteins (typically F is heavily altered in its cytoplasmic domain), 5) H protein is transported poorly to the cell surface, 6) F and H proteins maintain tightly interdepending fusion functions, presumably to allow local cell fusion and MV ribonucleoprotein (RNP) spread through the CNS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8030963     DOI: 10.1111/j.1749-6632.1994.tb38934.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  29 in total

Review 1.  RNA editing by adenosine deaminases that act on RNA.

Authors:  Brenda L Bass
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

2.  Measles virus structural components are enriched into lipid raft microdomains: a potential cellular location for virus assembly.

Authors:  S N Manié; S de Breyne; S Debreyne; S Vincent; D Gerlier
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 3.  Subacute sclerosing panencephalitis.

Authors:  R K Garg
Journal:  Postgrad Med J       Date:  2002-02       Impact factor: 2.401

4.  The various Sendai virus C proteins are not functionally equivalent and exert both positive and negative effects on viral RNA accumulation during the course of infection.

Authors:  P Latorre; T Cadd; M Itoh; J Curran; D Kolakofsky
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

5.  Case of the month.

Authors:  P Wingenfeld; B Schmidt; U Querfeld; D Michalk
Journal:  Eur J Pediatr       Date:  1996-03       Impact factor: 3.183

6.  Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts.

Authors:  M Kumar; G G Carmichael
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

7.  Characterization of measles virus strains causing SSPE: a study of 11 cases.

Authors:  L Jin; S Beard; R Hunjan; D W G Brown; E Miller
Journal:  J Neurovirol       Date:  2002-08       Impact factor: 2.643

8.  Mutant fusion proteins with enhanced fusion activity promote measles virus spread in human neuronal cells and brains of suckling hamsters.

Authors:  Shumpei Watanabe; Yuta Shirogane; Satoshi O Suzuki; Satoshi Ikegame; Ritsuko Koga; Yusuke Yanagi
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  Immune response-mediated protection of adult but not neonatal mice from neuron-restricted measles virus infection and central nervous system disease.

Authors:  D M Lawrence; M M Vaughn; A R Belman; J S Cole; G F Rall
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 10.  Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes.

Authors:  M Kumar; G G Carmichael
Journal:  Microbiol Mol Biol Rev       Date:  1998-12       Impact factor: 11.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.